M. Kokubo et al., Concurrent chemoradiotherapy combined with intraoperative radiotherapy forlocally advanced pancreatic cancer: A feasibility study, ONCOL REP, 7(4), 2000, pp. 773-776
Initial clinical results of concurrent chemoradiotherapy combined with high
-dose intraoperative radiotherapy (IOR) for locally advanced pancreatic can
cer were analyzed. Between June 1996 and May 1999, 6 patients with locally
advanced pancreatic cancer without distant metastasis were treated with pre
operative concurrent chemoradiotherapy followed by IOR. Preoperative radiat
ion therapy was given by the dynamic are conformal technique with a daily f
raction of 1.8 Gy to a total dose of 45 Gy in 5 weeks. Cisplatin (5 mg/day
for 4 weeks) and 5-fluorouracil (250 mg/day for 5 weeks) were administered
continuously during preoperative radiation therapy. IOR as a single dose of
28 or 30 Gy was given to the gross tumor volume using electron beams of 15
- to 22-MeV. Concurrent chemoradiotherapy was well tolerated, although all
of the patients complained of nausea and fatigue. Two patients developed gr
ade III leukopenia. No other serious acute toxicity was noted. The median s
urvival time of the 6 patients was 17.5 months, which was significantly lon
ger than that of our historical control treated with external radiation the
rapy with IOR (8 months), although the difference in survival was borderlin
e significant (p=0.068). Concurrent chemoradiotherapy followed by high-dose
IOR was well tolerated in patients with locally advanced pancreatic cancer
, and the initial clinical results appeared promising.